Identifying targetable apoptotic vulnerabilities for the treatment of AL amyloidosis
确定治疗 AL 淀粉样变性的靶向凋亡脆弱性
基本信息
- 批准号:10376814
- 负责人:
- 金额:$ 35.09万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-04-15 至 2024-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressApoptosisApoptoticAutologous Bone Marrow TransplantationAutologous Stem Cell TransplantationBCL2 geneBCL2L1 geneBiological MarkersBone MarrowBortezomibCellsClinicClinicalCytotoxic ChemotherapyDataDependenceDepositionDevelopmentDiagnosisDiseaseDisease ProgressionDisease remissionElderlyExhibitsFDA approvedFamilyHematopoieticImmunocompromised HostImmunomodulatorsImpaired Renal FunctionIn VitroIn complete remissionInjectionsInvestigationInvestigational TherapiesLeadLightLight-Chain ImmunoglobulinsMCL1 geneMalignant NeoplasmsMeasurementMeasuresMolecularMultiple MyelomaMusOrganOutcomePathogenesisPathway interactionsPatient AgentsPatient-Focused OutcomesPatientsPlasma CellsPopulationProductionProteasome InhibitorProtein FamilyProteinsRelapseResearchResearch PersonnelResistanceStressTestingTherapeuticToxic effectTreatment EfficacyTreatment ProtocolsUp-Regulationbasecancer cellcancer typechemotherapyclinical biomarkersclinical translationheart functionhuman modelimprovedin vivoindividualized medicineinhibitorinnovationmimeticsnovelnovel markerpatient derived xenograft modelpatient responsepreventprimary amyloidosis of light chain typeprospectiveproteotoxicityrational designresearch clinical testingresponsesmall molecule inhibitortherapeutic targettherapy designtooltreatment responsetreatment strategy
项目摘要
ABSTRACT
Immunoglobulin light chain (AL) amyloidosis is a highly lethal disorder characterized by the production and
deposition of fibrillogenic immunoglobulin light chains in vital organs. These misfolded light chains are
produced by a clonal population of diseased plasma cells, which are therapeutically targeted with the use of
proteasome inhibitors and immunomodulatory agents. However, these treatment regimens were developed for
the more common plasma cell disease multiple myeloma and have only limited efficacy in AL amyloidosis as
demonstrated by the 2-3 year median survival for patients that do not receive an autologous stem cell
transplant. Improved therapies for patients diagnosed with AL amyloidosis are therefore urgently needed,
especially well-tolerated treatments that are able to facilitate long-term remissions. We have previously
discovered that the state of the apoptosis pathway in cells, both in vitro and in the clinic, profoundly alters their
chemosensitivity and clinical outcomes. In addition, a preponderance of evidence demonstrates that
upregulation of pro-survival proteins from the BCL-2 family including BCL-2, BCL-XL and MCL-1 can be major
drivers of therapy resistance across multiple cancer types, highlighting the importance of this pathway in
governing responses to chemotherapy. The recent development of novel small-molecule inhibitors of the major
pro-survival proteins from the BCL-2 family has created an unprecedented opportunity to target apoptotic
dependencies in cancer cells, a strategy that may be particularly effective in the dysfunctional clonal plasma
cells that drive AL amyloidosis. However, the landscape of apoptotic dependencies in AL amyloidosis and how
they may be exploited to improve patient responses is not known. Using primary bone marrow-derived clonal
plasma cells from both treatment-naïve and treated AL amyloidosis patients, we have recently discovered that
clonal plasma cells exhibit strong dependencies on BCL-2 family proteins, which change dramatically in
response to treatment with existing front-line therapies. Our central hypothesis is that BH3 mimetics will be
highly effective agents for the treatment of clonal plasma cells in patients with AL amyloidosis, both as single
agents and in combination with front-line therapies. To test this hypothesis, we will 1) identify apoptotic
dependencies in clonal plasma cells from AL amyloidosis patients at baseline and during treatment with front-
line and experimental therapies; 2) investigate molecular mechanisms regulating apoptotic dependencies in AL
amyloidosis clonal plasma cells and how they may be used as clinical biomarkers; and 3) develop mouse PDX
models of AL amyloidosis to study disease development and progression as well as BH3 mimetic efficacy and
toxicity. This study addresses the important problem of limited therapeutic options for patients diagnosed with
AL amyloidosis by identifying highly-efficacious therapeutic approaches utilizing BH3 mimetics in this disease.
If successful, we expect to meaningfully improve patient outcomes and be a step closer to eventual cures.
摘要
免疫球蛋白轻链(AL)淀粉样变性是一种高度致命的疾病,其特征在于产生和
重要器官中纤维形成免疫球蛋白轻链的沉积。这些错误折叠的轻链是
由患病浆细胞的克隆群体产生,其通过使用
蛋白酶体抑制剂和免疫调节剂。然而,这些治疗方案是为
更常见的浆细胞疾病多发性骨髓瘤,而在AL淀粉样变性中仅具有有限的疗效,
未接受自体干细胞治疗的患者的中位生存期为2-3年
移植因此,迫切需要改善诊断为AL淀粉样变性的患者的疗法,
特别是耐受性良好的治疗,能够促进长期缓解。我们先前已经
发现细胞凋亡途径的状态,无论是在体外还是在临床上,都深刻地改变了它们的
化疗敏感性和临床结果。此外,大量证据表明,
来自BCL-2家族的促存活蛋白(包括BCL-2、BCL-XL和MCL-1)的上调可能是主要的
在多种癌症类型的治疗耐药性的驱动因素,突出了这一途径的重要性,
控制对化疗的反应本文综述了近年来新型小分子抗肿瘤药物的研究进展,
来自BCL-2家族的促存活蛋白为靶向凋亡创造了前所未有的机会,
依赖性的癌细胞,一种策略,可能是特别有效的功能失调克隆血浆
导致AL淀粉样变性的细胞然而,AL淀粉样变性中的凋亡依赖性以及如何
目前尚不清楚它们是否可以用来改善患者的反应。使用原代骨髓来源的克隆
从初治和已治AL淀粉样变性患者的浆细胞中,我们最近发现,
克隆性浆细胞表现出对BCL-2家族蛋白的强烈依赖性,这些蛋白在
对现有一线治疗的反应。我们的中心假设是,BH 3模拟物将是
治疗AL淀粉样变性患者克隆浆细胞的高效药物,
药物和与一线治疗联合使用。为了验证这一假设,我们将1)鉴定凋亡
AL淀粉样变性患者在基线时和在前-
线和实验性疗法; 2)研究调节AL中凋亡依赖性的分子机制
淀粉样变性克隆浆细胞以及它们如何可用作临床生物标志物;以及3)开发小鼠PDX
AL淀粉样变性模型,以研究疾病发展和进展以及BH 3模拟功效,
毒性这项研究解决了诊断为糖尿病的患者治疗选择有限的重要问题。
AL淀粉样变性,通过确定在这种疾病中利用BH 3模拟物的高效治疗方法。
如果成功,我们希望有意义地改善患者的预后,并向最终治愈迈进一步。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kristopher Andrew Sarosiek其他文献
Kristopher Andrew Sarosiek的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kristopher Andrew Sarosiek', 18)}}的其他基金
Developmental regulation of apoptosis as a modifiable driver of radiotherapy-induced neurocognitive impairment in pediatric patients
细胞凋亡的发育调节作为儿科患者放疗引起的神经认知障碍的可改变驱动因素
- 批准号:
10561668 - 财政年份:2020
- 资助金额:
$ 35.09万 - 项目类别:
Identifying targetable apoptotic vulnerabilities for the treatment of AL amyloidosis
确定治疗 AL 淀粉样变性的靶向凋亡脆弱性
- 批准号:
10609467 - 财政年份:2020
- 资助金额:
$ 35.09万 - 项目类别:
Developmental regulation of apoptosis as a modifiable driver of radiotherapy-induced neurocognitive impairment in pediatric patients
细胞凋亡的发育调节作为儿科患者放疗引起的神经认知障碍的可改变驱动因素
- 批准号:
10371055 - 财政年份:2020
- 资助金额:
$ 35.09万 - 项目类别:
Regulation of apoptotic priming and competence in healthy and cancerous cells
健康细胞和癌细胞中凋亡启动和能力的调节
- 批准号:
8767377 - 财政年份:2014
- 资助金额:
$ 35.09万 - 项目类别:
Regulation of apoptotic priming and competence in healthy and cancerous cells
健康细胞和癌细胞中凋亡启动和能力的调节
- 批准号:
8918557 - 财政年份:2014
- 资助金额:
$ 35.09万 - 项目类别:
相似国自然基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
- 批准号:LBY21H010001
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
- 批准号:81703335
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
- 批准号:81670594
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
- 批准号:81470791
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
- 批准号:81301123
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
- 批准号:39500043
- 批准年份:1995
- 资助金额:9.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Spatial Restriction of Apoptotic Machinery during Neuronal Apoptosis and Pruning
神经元凋亡和修剪过程中凋亡机制的空间限制
- 批准号:
10596657 - 财政年份:2021
- 资助金额:
$ 35.09万 - 项目类别:
Spatial Restriction of Apoptotic Machinery during Neuronal Apoptosis and Pruning
神经元凋亡和修剪过程中凋亡机制的空间限制
- 批准号:
10417219 - 财政年份:2021
- 资助金额:
$ 35.09万 - 项目类别:
Examining the contribution of apoptosis repressor with caspase recruitment domain (ARC) to the anti-apoptotic effect of endurance training in skeletal muscle
检查具有半胱天冬酶募集结构域 (ARC) 的凋亡抑制因子对骨骼肌耐力训练的抗凋亡作用的贡献
- 批准号:
441952-2013 - 财政年份:2015
- 资助金额:
$ 35.09万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Examining the contribution of apoptosis repressor with caspase recruitment domain (ARC) to the anti-apoptotic effect of endurance training in skeletal muscle
检查具有半胱天冬酶募集结构域 (ARC) 的凋亡抑制因子对骨骼肌耐力训练的抗凋亡作用的贡献
- 批准号:
441952-2013 - 财政年份:2014
- 资助金额:
$ 35.09万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Understanding the activation of pro-apoptotic Bcl-2 family proteins for the development of modulators of apoptosis
了解促凋亡 Bcl-2 家族蛋白的激活以开发凋亡调节剂
- 批准号:
nhmrc : 1059331 - 财政年份:2014
- 资助金额:
$ 35.09万 - 项目类别:
Project Grants
Examining the contribution of apoptosis repressor with caspase recruitment domain (ARC) to the anti-apoptotic effect of endurance training in skeletal muscle
检查具有半胱天冬酶募集结构域 (ARC) 的凋亡抑制因子对骨骼肌耐力训练的抗凋亡作用的贡献
- 批准号:
441952-2013 - 财政年份:2013
- 资助金额:
$ 35.09万 - 项目类别:
Postgraduate Scholarships - Doctoral
Apoptotic Osteocytes Promote Chondrocyte Apoptosis via Soluble Factors
凋亡骨细胞通过可溶性因子促进软骨细胞凋亡
- 批准号:
251802 - 财政年份:2012
- 资助金额:
$ 35.09万 - 项目类别:
Studentship Programs
Defining the mechanism(s) by which the cellular inhibitor of apoptosis protein 2 (cIAP2) contributes to early stage atherosclerosis development by directly promoting the participation of key apoptotic pathways within lesion-associated macrophages
确定凋亡蛋白细胞抑制剂 2 (cIAP2) 通过直接促进病变相关巨噬细胞内关键凋亡途径的参与来促进早期动脉粥样硬化发展的机制
- 批准号:
191299 - 财政年份:2009
- 资助金额:
$ 35.09万 - 项目类别:
Operating Grants
ATP release during apoptosis and its relevance to apoptotic cell clearance
凋亡过程中 ATP 释放及其与凋亡细胞清除的相关性
- 批准号:
8075522 - 财政年份:2009
- 资助金额:
$ 35.09万 - 项目类别:
ATP release during apoptosis and its relevance to apoptotic cell clearance
凋亡过程中 ATP 释放及其与凋亡细胞清除的相关性
- 批准号:
7676912 - 财政年份:2009
- 资助金额:
$ 35.09万 - 项目类别: